Compare CHH & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHH | SRRK |
|---|---|---|
| Founded | 1939 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.6B |
| IPO Year | 1997 | 2018 |
| Metric | CHH | SRRK |
|---|---|---|
| Price | $100.58 | $45.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 11 |
| Target Price | ★ $112.92 | $55.40 |
| AVG Volume (30 Days) | 512.4K | ★ 1.4M |
| Earning Date | 05-07-2026 | 03-03-2026 |
| Dividend Yield | ★ 1.16% | N/A |
| EPS Growth | ★ 27.42 | N/A |
| EPS | ★ 7.90 | N/A |
| Revenue | ★ $1,596,793,000.00 | N/A |
| Revenue This Year | $66.74 | N/A |
| Revenue Next Year | $0.49 | $550.26 |
| P/E Ratio | $12.56 | ★ N/A |
| Revenue Growth | ★ 0.75 | N/A |
| 52 Week Low | $84.04 | $22.71 |
| 52 Week High | $136.45 | $49.82 |
| Indicator | CHH | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 48.78 | 53.21 |
| Support Level | $99.40 | $41.07 |
| Resistance Level | $103.62 | $48.29 |
| Average True Range (ATR) | 3.01 | 2.39 |
| MACD | 0.31 | 0.33 |
| Stochastic Oscillator | 79.53 | 70.39 |
At year-end 2025, Choice Hotels operated 657,000 rooms across the economy, midscale, upscale, and extended-stay segments. Comfort Inn and Comfort Suites are the largest brands (27% of the company's total rooms), while Ascend and Cambria (10%) are lifestyle and select-service brands, and WoodSpring (5%) is the company's largest extended-stay brand. Choice closed on its Radisson acquisition in August 2022, which added about 70,000 rooms. Franchises account for 100% of total revenue, and the United States represented 78% of total rooms in 2024.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.